Through this strategy, we identified ARL2 as a novel circulating biomarker for the detection of the comorbidity of SD and IS, which gives our study a significant clinical advantage for non-invasive, rapid screening, identification of people at high risk for sleep disorders, and prevention of stroke. This evidence concerns the gene ARL2 and Stroke.